192 related articles for article (PubMed ID: 23921728)
1. Uncommon ventures launch to tackle uncommon diseases.
Dolgin E
Nat Med; 2013 Aug; 19(8):950-1. PubMed ID: 23921728
[No Abstract] [Full Text] [Related]
2. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
John JE
Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
[No Abstract] [Full Text] [Related]
3. New models for pharmaceutical innovation in low-income countries.
Ardal C; Iversen JH; Myhr K
Tidsskr Nor Laegeforen; 2011 Oct; 131(20):2016-8. PubMed ID: 22016131
[No Abstract] [Full Text] [Related]
4. The European rare diseases therapeutic initiative.
Fischer A; Borensztein P; Roussel C
PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832
[TBL] [Abstract][Full Text] [Related]
5. [Cohorts and registers: Which public/private partnerships to choose?].
Jouan-Flahault C; Landais P; Thomas R; Parker S; Genevaz D
Presse Med; 2012 May; 41 Suppl 1():S15-9. PubMed ID: 22464892
[No Abstract] [Full Text] [Related]
6. R&D policy, agency costs and innovation in personalized medicine.
Yin W
J Health Econ; 2009 Sep; 28(5):950-62. PubMed ID: 19671480
[TBL] [Abstract][Full Text] [Related]
7. Orphan drug development: an economically viable strategy for biopharma R&D.
Meekings KN; Williams CS; Arrowsmith JE
Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309
[TBL] [Abstract][Full Text] [Related]
8. A new era of hope for the world's most neglected diseases.
The
PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
[TBL] [Abstract][Full Text] [Related]
9. Orphanage at the FDA.
Chen E
J Cardiovasc Transl Res; 2012 Oct; 5(5):735-6. PubMed ID: 21080134
[No Abstract] [Full Text] [Related]
10. [Not Available].
Med Sci (Paris); 2016 Apr; 32 Spec No 1():29-33. PubMed ID: 27137859
[No Abstract] [Full Text] [Related]
11. [Conference 1. An economic observatory for orphan drugs: myth or reality?].
Duguet C; Ferry A
Med Sci (Paris); 2014 Apr; 30 Spe(1):21-3. PubMed ID: 24755173
[No Abstract] [Full Text] [Related]
12. Financing drug discovery for orphan diseases.
Fagnan DE; Gromatzky AA; Stein RM; Fernandez JM; Lo AW
Drug Discov Today; 2014 May; 19(5):533-8. PubMed ID: 24269746
[TBL] [Abstract][Full Text] [Related]
13. Rarefied drug pricing.
Nat Biotechnol; 2014 May; 32(5):398. PubMed ID: 24811493
[No Abstract] [Full Text] [Related]
14. Birgitte Volck.
Nat Rev Drug Discov; 2017 May; 16(6):378-379. PubMed ID: 28559559
[No Abstract] [Full Text] [Related]
15. Big pharma moves from 'blockbusters' to 'niche busters'.
Dolgin E
Nat Med; 2010 Aug; 16(8):837. PubMed ID: 20689537
[No Abstract] [Full Text] [Related]
16. New drugs carry hefty price tags. Makers of leading-edge orphan products asked to cut prices, take smaller profits.
Lee J
Mod Healthc; 2013 Oct; 43(40):14. PubMed ID: 24340725
[No Abstract] [Full Text] [Related]
17. Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery.
Wood J; Sames L; Moore A; Ekins S
Drug Discov Today; 2013 Nov; 18(21-22):1043-51. PubMed ID: 23968993
[TBL] [Abstract][Full Text] [Related]
18. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.
Kumar Kakkar A; Dahiya N
Drug Dev Res; 2014 Jun; 75(4):231-4. PubMed ID: 24829189
[TBL] [Abstract][Full Text] [Related]
19. Reforming the Orphan Drug Act for the 21st Century.
Sarpatwari A; Kesselheim AS
N Engl J Med; 2019 Jul; 381(2):106-108. PubMed ID: 31291512
[No Abstract] [Full Text] [Related]
20. The balancing act of orphan drug pricing.
The Lancet
Lancet; 2017 Dec; 390(10113):2606. PubMed ID: 29256396
[No Abstract] [Full Text] [Related]
[Next] [New Search]
